Inhibiting aggressive breast cancer progression by targeting cell changes
Official title: Targeting lineage plasticity to inhibit basal-like breast cancer progression
Funded at Albert Einstein College of Medicine · NIH-11049844 · Data updated 2026-11-12
This study is looking at a tough type of breast cancer called basal-like breast cancer, which mainly affects younger women and those of African descent, to find out how it develops and to discover new ways to stop it from getting worse.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $543,221 |
| NIH project number | 1R01CA289734-01A1 |
| Project ID | NIH-11049844 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include younger women, particularly those of African descent or those with BRCA1 mutations, who are diagnosed with basal-like breast cancer.
✕Less likely to help
Patients with other subtypes of breast cancer or those who do not have the specific genetic factors associated with basal-like breast cancer may not benefit from this research.
What this research studies
This research focuses on understanding and targeting the aggressive subtype of breast cancer known as basal-like breast cancer (BLBC), which primarily affects younger women and those of African ancestry. The study aims to investigate the cellular changes that lead to the progression of this cancer type, particularly how certain cells can revert to a more primitive state that promotes malignancy. By exploring the role of specific genetic factors, the research seeks to develop new strategies to prevent the transition from precancerous conditions to BLBC, potentially leading to more effective treatments.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies for basal-like breast cancer, improving outcomes for affected patients.
How similar studies have gone: Previous studies have shown promise in targeting lineage plasticity in cancer, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Guo, Wenjun — Albert Einstein College of Medicine
- Study coordinator: Guo, Wenjun
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.